Week In Review: Suzhou Innovent Files For HK IPO -- $500 Million Raise Rumored

Innovent Biologics of Suzhou has filed to IPO on the Hong Kong Exchange under its new rules for pre-revenue biopharmas. The company plans to raise as much as $500 million, according to media reports, at a valuation of over $1 billion.